Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Rhea-AI Summary
Daxor (Nasdaq: DXR) issued a mid‑year 2026 shareholder letter detailing commercial, financial, and clinical progress. The company completed a $9 million registered direct offering in January 2026 (765,958 shares at $11.75), used mainly to retire $1.17 million of short‑term debt and fund manufacturing and inventory investments.
As of June 30, 2026, unaudited net assets were $51.8 million, up $5.9 million from year‑end, with NAV per share of $8.88 versus $9.07 on December 31, 2025. Daxor reports being debt‑free with 5,838,224 common shares outstanding and no warrants or convertibles. Unaudited kit sales rose 16% year‑over‑year in the first half, while the sales team is being expanded by 300% under a new SVP of Sales.
The company highlighted strong demand for its FDA‑cleared next‑generation Blood Volume Analyzer, new U.S. patent 12,635,917 B2 for remote blood volume monitoring, and clinical data showing substantial reductions in readmissions, mortality, and length of stay when care is guided by its Blood Volume Analysis technology.
Positive
- Unaudited kit sales grew 16% in 1H 2026 versus 1H 2025
- Completed $9 million registered direct offering at $11.75 per share
- Net assets increased $5.94 million to $51.83 million by June 30, 2026
- Retired $1.17 million of short‑term debt; now debt‑free
- Capital structure has 5,838,224 common shares and no warrants or convertibles
- Clinical data show up to 86% reduction in 1‑year mortality with BVA‑guided care
Negative
- NAV per share declined from $9.07 to $8.88 in 1H 2026 despite accretive offering
News Explained
As of September 1, 2026, Daxor's reporting transition remains pending, and its more-than-fifteen system indications are not yet completed placements.
In its
The immediate structural consequence is that Daxor continues under its existing registered closed-end investment company status rather than the planned reporting regime.
Daxor also reports more than fifteen indications of interest from hospitals and practices for its next-generation BVA system.
These are prospective indications rather than completed placements; the company anticipates placing the units over the next several quarters.
The Commission's order is the named resolution point for the reporting transition, while finalized system placements are the stated milestone for converting the indicated demand into installed units.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 29 | Outpatient program launch | Positive | -0.3% | Kansas ezBVA Lab launch expanded Daxor's outpatient footprint |
| Jul 07 | Conference exhibition | Positive | -0.3% | First Dysautonomia International Conference exhibition highlighted next-generation BVA |
| Jun 02 | Patent issuance | Positive | +2.9% | USPTO issued patent covering a remote blood volume monitor |
| Apr 28 | Conference clinical data | Positive | +5.4% | MedAxiom event highlighted mortality, readmission, and length-of-stay outcomes |
| Apr 08 | Customer program launch | Positive | +2.3% | Ohio cardiology center launched a new BVA program |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive Daxor announcements produced both aligned gains and divergences, with three of five events followed by negative or positive moves inconsistent with a uniform response.
Key Terms
fda 510(k) clearance regulatory
clia-certified regulatory
radiopharmaceutical medical
albumin escape rate medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.
Dear Valued Shareholders,
“It’s still Day 1.” — Jeff Bezos
That's exactly how we think about where Daxor stands today. Everything we have accomplished to date — the FDA clearance of our next-generation analyzer, our new patent, our clinical data, our acquisition of our supplier, Isotex Diagnostics, our capital raise — has been about building the launch pad, not the destination. The real growth is still in front of us, and the first half of 2026 was about putting the pieces in place to grow aggressively from here.
Management remains more excited than ever about the opportunity in front of us: to build a substantial business that meaningfully improves patient outcomes while reducing costs across the healthcare system. Over the first half of 2026, we've been deliberately putting the building blocks in place — improving our product, increasing production, growing our sales organization, and generating new clinical evidence — to make that opportunity a reality.
In January, we completed a very clean
Commercial Expansion & Sales Leadership
With capital now in place, we are focused on aggressively growing our commercial team. Unaudited kit sales grew
Alongside this team build-out, our dual-solution strategy — on-site BVA analyzers plus our CLIA-certified, zero-capital ezBVA Lab send-out service — drove new account activity during the period:
- Tennessee (February): New outpatient BVA program, Southern Middle Tennessee
- Ohio (April): High-volume cardiology center, Southwest Ohio
We also maintained an active conference presence during the first half — SCCM, ACC.26, MedAxiom CV Transforum, and the iAccess Alpha investor conference — building clinical and investor awareness in parallel.
Next-Generation BVA System: Building the Pipeline
Demand for our next-generation BVA system has been strong. We have received indications of interest from more than fifteen hospitals and practices to acquire the new system, and we anticipate placing these units over the next several quarters as we ramp production and installation capacity — the manufacturing investment described in the Financial Position section below is directly in service of this rollout. Each new placement is also expected to drive incremental kit sales demand and to open new points of care in the outpatient setting, extending the reach of precision blood volume measurement described above to a broader population of at-risk patients.
Financial Position: Debt-Free, Clean Capital Structure, Capital Deployed for Growth
The financial and operating figures discussed in this section are unaudited, derived from our Form N-CSR for the six months ended June 30, 2026, and are subject to adjustment.
As of June 30, 2026, Daxor's net assets were
Daxor's capital structure is straightforward: we have no warrants, convertible notes, or other derivative securities outstanding — just 5,838,224 shares of common stock outstanding at June 30, 2026 (6,313,224 shares issued, less 475,000 shares held in treasury). Our equity incentive awards — 216,984 stock options at a
Importantly, Daxor also carries no outstanding debt. Using a portion of the January offering proceeds, we retired
Backing out that one-time debt retirement, the operating division's underlying investment for the six-month period was
- Radiopharmaceutical manufacturing buildout: Capital expenditures to upgrade our Oak Ridge, TN facility to bring in-house manufacturing of the radiopharmaceutical products we are acquiring from Isotex Diagnostics online. Once fully transitioned, we expect this to boost our kit output capacity by more than
500% over the next 12 months, while also adding an additional radiopharmaceutical product, Glofil, to our portfolio. - Next-generation BVA production capacity: Purchases of parts and tooling to manufacture our new next-generation Blood Volume Analyzer.
- Inventory build for account placements: Increased inventory of single-use kit cartridges and BVA analyzer components to support new system placements at accounts as we scale commercially.
We see this first half as patient capital at work: a clean, low-dilution capital structure, a debt-free balance sheet, safety and liquidity preserved through short-term Treasuries, and direct investment in the manufacturing capacity and inventory needed to meet commercial demand for our next-generation platform.
Corporate Structure & Strategic Realignment
On February 10, 2026, we announced our intention to transition primary regulatory reporting from the Investment Company Act of 1940 to the Securities Exchange Act of 1934 — formal recognition that Daxor operates as a medical diagnostics and technology company. We previously anticipated completing this transition by the end of the second quarter of 2026. The Commission has not yet acted on our application, and we remain a registered closed-end investment company as of the date of this letter. We have responded to all requests from the staff in a timely manner but cannot predict when an order will be issued. This move is expected to simplify disclosures and provide investors with standardized GAAP metrics comparable to peer diagnostic companies.
In December 2025, we sold our remaining investment portfolio positions and currently hold no common or preferred stock positions. Our time and resources are now fully dedicated to the Blood Volume Analysis business and the radiopharmaceutical manufacturing capability we are building out.
Intellectual Property
On June 2, 2026, the USPTO issued U.S. Patent No. 12,635,917 B2, “Remote Blood Volume Monitor.” This extends our IP moat beyond point-of-care testing into continuous, wearable-sensor-based monitoring — anchoring a single precise BVA baseline to ongoing non-invasive (PPG) tracking to flag clinically meaningful volume shifts in real time. This opens a path toward chronic disease management applications in heart failure, syncope, anemia, and polycythemia.
Research & Development
Our R&D remained centered during the period on the next-generation Blood Volume Analyzer that received FDA 510(k) clearance in August of 2025 and an approved software upgrade in June of 2026 — developed under a U.S. Department of Defense contract, delivering results three times faster than our legacy BVA-100 in a seven-pound, portable form factor. As described above, offering proceeds are now directly funding the manufacturing capacity — parts, tooling, and inventory — needed to build and place these units, alongside the R&D reflected in the remote-monitoring patent.
The Clinical and Health-Economic Case for Precision Blood Volume Measurement
At its core, Daxor's mission addresses what we've long described as healthcare's multi-billion-dollar silent crisis: the inability to precisely measure blood volume. Clinicians have historically had to rely on indirect proxies — vital signs, weight, clinical judgment, or imprecise formulas — to estimate a patient's true intravascular volume status. These proxies are frequently wrong, and the consequences of getting volume status wrong are significant: under- or over-resuscitation in the ICU, misdiagnosed or mistreated heart failure, prolonged hospital stays, and avoidable readmissions.
BVA closes that gap. As the only FDA-cleared diagnostic providing an objective, patient-specific quantification of a patient's total blood volume status and composition, it gives clinicians a direct, precise measurement rather than an inference — and that precision changes the direction of care. In the inpatient setting, this means guiding fluid management and diuresis decisions in heart failure and critical care patients with a level of accuracy that clinical scoring systems alone cannot match. In the outpatient setting, it means earlier and more accurate identification of volume overload or depletion in chronic heart failure and other at-risk patients, before those conditions progress to a point requiring hospitalization.
The health-economic case follows directly from the clinical one. The outcomes data we've generated and continue to expand — including the reductions in readmissions, mortality, and length of stay referenced below — aren't just clinical wins; they represent meaningful cost savings for hospitals and health systems operating under increasing value-based care pressure. A more precise diagnostic, applied at the right point in a patient's care journey, doesn't just improve outcomes for the patient — it reduces the downstream resource burden on the healthcare system as a whole. This dual benefit, to patient and system alike, is the foundation of our commercial strategy across both hospital-based analyzer placements and our outpatient ezBVA Lab service.
Clinical Validation
During the first half of 2026:
- SCCM 2026 (March): New data presented with Children's National Hospital validated BVA's Albumin Escape Rate as a uniquely accurate, direct measure of capillary leak — outperforming traditional clinical scoring indices, which showed weak, non-significant correlation with actual measured leak.
- ACC.26 (March): Highlighted peer-reviewed data showing BVA-guided care associated with a
56% reduction in 30-day readmissions and an82% reduction in 30-day mortality. - MedAxiom CV Transforum Spring '26 (April/May): Reinforced outcomes data including an
86% reduction in 1-year mortality and a55% reduction in length of stay when BVA is performed on admission.
Recent Developments
Since the close of the reporting period, Daxor has continued this momentum, including a new outpatient BVA program launch in eastern Kansas (July) and our first-time exhibition at the Dysautonomia International Conference (July), marking an initial step into a new indication area — autonomic disorders.
Looking Ahead
With more than fifteen indications of interest in hand for our next-generation BVA system, a strengthened commercial team now in place under new sales leadership, and a debt-free balance sheet supporting continued investment in manufacturing capacity, we head into the second half of 2026 well positioned to convert this pipeline into placements. We expect unit placements to ramp over the next several quarters, driving incremental kit sales and expanding our footprint into new outpatient points of care. We look forward to updating shareholders on our progress as these placements are finalized.
In closing, the first half of 2026 was about building the launch pad — in our people, our manufacturing capacity, and our balance sheet — for the growth we believe lies ahead. For Daxor, it's still Day 1. We thank you for your continued trust and investment in Daxor Corporation.
Sincerely,
Michael Feldschuh President and CEO Daxor Corporation
Any shareholder who is interested in learning more about our medical instrumentation and biotechnology operations should visit our website at www.daxor.com or contact our investor relations representative Bret Shapiro of CORE IR at www.coreir.com for more detailed information. We periodically issue press releases regarding research reports and placements of the Daxor BVA system in hospitals. Sign up to receive news on Daxor’s innovative technology and investor announcements HERE.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com
